Novo Nordisk A/S Sponsored ADR (NVO)
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
Hims & Hers stock crashes over 20% on Wegovy shocker
Hims & Hers Health (NYSE: HIMS) stock has plunged sharply after Novo Nordisk (NYSE: NVO) announced it was severing ties with the telehealth firm over concerns about the distribution of its weight loss drug, Wegovy.
Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautious
Novo Nordisk (NYSE:NVO) delivered promising data over the weekend for its next-generation weight-loss injection, CagriSema, showing it can achieve weight reductions on par with the most effective treatments currently available. Yet the subdued market reaction on Monday suggests growing investor unease about how the Danish drugmaker will hold its lead in a rapidly crowding space.
Novo Nordisk And Its Real Value
Novo Nordisk remains fundamentally strong with robust earnings growth, high ROE, ROIC, and gross margins, despite recent CEO change and short-term market concerns. The stock appears undervalued, trading below estimated fair value, and offers a potential 12-14% annual return for long-term investors. Key risks include US drug price negotiations, especially for Ozempic and Wegovy, which could impact revenue and create short-term volatility.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (June 2025)
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Novo Nordisk: The Strength To Withstand Challenges
Novo Nordisk's price has regained momentum in recent weeks after seeing a big slump earlier in 2025. With strong financials, and robust profit estimates even after a downgrade in outlook, NVO could continue to rise. There are risks to the stock as well, though, from losing market share to compounder versions of its blockbuster GLP-1 drugs.
